Kuypers Kim P C
Department of Neuropsychology & Psychopharmacology, Faculty of Psychology & Neuroscience, Maastricht University, PB 616, 6200 MD, the Netherlands.
Ther Adv Psychopharmacol. 2020 Aug 27;10:2045125320950567. doi: 10.1177/2045125320950567. eCollection 2020.
Microdosing psychedelics is the repeated use of small doses of, for example, lysergic acid diethylamide (LSD) and psilocybin, typically for a few weeks. Despite the popular and scientific attention in recent years, and claims by users that it has therapeutic value in affective disorders like depression, little scientific knowledge is available to back this. The purpose of this review was to investigate whether there are scientific grounds to state that this practice could be helpful in the treatment of affective disorders, and safe to use repeatedly. To that end, the literature (PubMed, MedLine) was searched, looking for (controlled) experimental studies with low doses of LSD and/or psilocybin, in healthy volunteers and patient samples. After a selection process and the addition of relevant articles, 14 experimental studies entered this review. Findings show that both LSD (10-20 mcg) and psilocybin (<1-3 mg) have subtle (positive) effects on cognitive processes (time perception, convergent and divergent thinking) and brain regions involved in affective processes. Besides the pleasant experience, increased anxiety and a cycling pattern of depressive and euphoric mood were also found. With regard to safety, it was demonstrated that low doses are well tolerated (in healthy volunteers) and have no-to-minimal effects on physiological measures. While it is yet unclear whether psychedelic microdosing is of therapeutic value for depression, the aforementioned effects on selective processes suggest that low doses of psychedelics could play a role in depression by inducing some kind of cognitive flexibility, which might lead to decreased rumination. While previous studies were conducted mostly in small samples of healthy volunteers, future placebo-controlled clinical trials in depressed patients are required to understand the therapeutic value of microdosing psychedelics, how this differs from therapy using full psychedelic doses, and whether different psychedelics have different effect patterns. The proposed research will give new insights into the potential of future alternative psychiatric treatment forms that are fiercely needed.
微剂量使用迷幻剂是指反复使用小剂量的,例如麦角酸二乙酰胺(LSD)和裸盖菇素,通常持续几周时间。尽管近年来受到了大众和科学界的关注,且使用者声称其对抑郁症等情感障碍具有治疗价值,但几乎没有科学知识能支持这一说法。本综述的目的是调查是否有科学依据表明这种做法有助于治疗情感障碍,以及反复使用是否安全。为此,检索了文献(PubMed、MedLine),寻找在健康志愿者和患者样本中进行的低剂量LSD和/或裸盖菇素的(对照)实验研究。经过筛选过程并补充相关文章后,14项实验研究纳入了本综述。研究结果表明,LSD(10 - 20微克)和裸盖菇素(<1 - 3毫克)对认知过程(时间感知、聚合思维和发散思维)以及涉及情感过程的脑区都有微妙的(积极)影响。除了愉快的体验外,还发现焦虑增加以及抑郁和欣快情绪的循环模式。关于安全性,已证明低剂量耐受性良好(在健康志愿者中),对生理指标无影响或影响极小。虽然尚不清楚迷幻剂微剂量使用对抑郁症是否具有治疗价值,但上述对选择性过程的影响表明,低剂量迷幻剂可能通过诱导某种认知灵活性在抑郁症中发挥作用,这可能导致反刍减少。虽然之前的研究大多在少量健康志愿者样本中进行,但未来需要在抑郁症患者中开展安慰剂对照临床试验,以了解迷幻剂微剂量使用的治疗价值、与使用全剂量迷幻剂治疗的差异,以及不同迷幻剂是否有不同的效应模式。拟议的研究将为迫切需要的未来替代精神治疗形式的潜力提供新的见解。